$ADTX
Aditxt, Inc. Stock $adtx

$adtx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000121390023039839 Filed on May 15, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue	$218.4K	$210.3K
YoY Change	3.87%
Cost Of Revenue	$178.3K	$188.1K
YoY Change	-5.19%
Gross Profit	$40.11K	$22.21K
YoY Change	80.58%
Gross Profit Margin	18.36%	10.56%
Selling, General & Admin	$4.434M	$4.711M
YoY Change	-5.87%	-8.71%
% of Gross Profit	11056.85%	21210.09%
Research & Development	$1.388M	$1.428M
YoY Change	-2.86%	51.96%
% of Gross Profit	3459.68%	6431.25%
Depreciation & Amortization	$109.9K	$123.6K
YoY Change	-11.09%	23.6%
% of Gross Profit	274.01%	556.51%
Operating Expenses	$5.822M	$6.139M
YoY Change	-5.17%	0.81%
Operating Profit	-$5.782M	-$6.117M
YoY Change	-5.48%	0.44%
Interest Expense	-$202.8K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$202.8K	$58.96K
YoY Change	-443.98%
Pretax Income	-$5.985M	-$6.059M
YoY Change	-1.23%	-5.03%
Income Tax
% Of Pretax Income
Net Earnings	-$5.985M	-$6.059M
YoY Change	-1.23%	-5.02%
Net Earnings / Revenue	-2740.06%	-2881.46%
Basic Earnings Per Share	-$1.31	-$6.80
Diluted Earnings Per Share	-$1.31	-$135.9K
COMMON SHARES
Basic Shares Outstanding	4.563M shares	891.6K shares
Diluted Shares Outstanding	4.563M shares	891.6K shares

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$302.5K	$2.115M
YoY Change	-85.7%	-84.95%
Cash & Equivalents	$302.5K	$2.115M
Short-Term Investments
Other Short-Term Assets	$548.4K	$534.9K
YoY Change	2.52%	-29.61%
Inventory	$763.5K	$1.042M
Prepaid Expenses	$548.4K
Receivables	$329.0K	$248.8K
Other Receivables	$0.00	$500.0K
Total Short-Term Assets	$1.943M	$4.441M
YoY Change	-56.24%	-70.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.214M	$6.202M
YoY Change	-64.3%	118.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$410.3K	$446.8K
YoY Change	-8.18%	538.34%
Other Assets	$50.00K	$515.1K
YoY Change	-90.29%
Total Long-Term Assets	$5.690M	$7.351M
YoY Change	-22.6%	129.01%
TOTAL ASSETS
Total Short-Term Assets	$1.943M	$4.441M
Total Long-Term Assets	$5.690M	$7.351M
Total Assets	$7.634M	$11.79M
YoY Change	-35.26%	-34.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.236M	$2.559M
YoY Change	26.46%	163.83%
Accrued Expenses	$1.095M	$1.138M
YoY Change	-3.8%	191.79%
Deferred Revenue
YoY Change
Short-Term Debt	$1.246M	$0.00
YoY Change
Long-Term Debt Due	$147.8K	$626.3K
YoY Change	-76.4%	-52.19%
Total Short-Term Liabilities	$5.910M	$4.515M
YoY Change	30.92%	32.78%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$1.655M	$2.555M
YoY Change	-35.2%	87.84%
Total Long-Term Liabilities	$1.655M	$2.555M
YoY Change	-35.2%	-21.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.910M	$4.515M
Total Long-Term Liabilities	$1.655M	$2.555M
Total Liabilities	$7.566M	$7.069M
YoY Change	7.02%	6.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$101.0M
YoY Change
Common Stock	$4.835K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$201.6K
YoY Change
Treasury Stock Shares
Shareholders Equity	$68.07K	$4.723M
YoY Change
Total Liabilities & Shareholders Equity	$7.634M	$11.79M
YoY Change	-35.26%	-34.56%

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$5.985M	-$6.059M
YoY Change	-1.23%	-5.02%
Depreciation, Depletion And Amortization	$109.9K	$123.6K
YoY Change	-11.09%	23.6%
Cash From Operating Activities	-$3.952M	-$5.199M
YoY Change	-23.99%	28.38%
INVESTING ACTIVITIES
Capital Expenditures	$5.050K	-$147.8K
YoY Change	-103.42%	-69.84%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$225.6K
YoY Change	-100.0%
Cash From Investing Activities	-$5.049K	-$373.4K
YoY Change	-98.65%	-23.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$507.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.491M	-184.2K
YoY Change	-909.38%	-102.28%
NET CHANGE
Cash From Operating Activities	-$3.952M	-5.199M
Cash From Investing Activities	-$5.049K	-373.4K
Cash From Financing Activities	$1.491M	-184.2K
Net Change In Cash	-$2.466M	-5.757M
YoY Change	-57.16%	-262.62%
FREE CASH FLOW
Cash From Operating Activities	-$3.952M	-$5.199M
Capital Expenditures	$5.050K	-$147.8K
Free Cash Flow	-$3.957M	-$5.052M
YoY Change	-21.67%	41.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39336
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Aditxt, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3204328
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	737 N. Fifth Street
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Richmond
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	23219
CY2023Q1	dei	City Area Code CityAreaCode	(650)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	870-1200
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	ADTX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6760064	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	302509	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2768640	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	329021	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	527961	usd
CY2023Q1	us-gaap	Public Utilities Inventory PublicUtilitiesInventory	763530	usd
CY2022Q4	us-gaap	Public Utilities Inventory PublicUtilitiesInventory	950093	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	548402	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	496869	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	1943462	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4743563	usd
CY2023Q1	adtx	Fixed Asset FixedAsset	2214016	usd
CY2022Q4	adtx	Fixed Asset FixedAsset	2318863	usd
CY2023Q1	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	80250	usd
CY2022Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	107000	usd
CY2023Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	410306	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	355366	usd
CY2023Q1	adtx	Right Of Use Asset Long Term RightOfUseAssetLongTerm	2935599	usd
CY2022Q4	adtx	Right Of Use Asset Long Term RightOfUseAssetLongTerm	3160457	usd
CY2023Q1	us-gaap	Deferred Costs DeferredCosts	50000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	50000	usd
CY2023Q1	us-gaap	Assets Assets	7633633	usd
CY2022Q4	us-gaap	Assets Assets	10735249	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3236290	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1958502	usd
CY2023Q1	adtx	Notes Payable Net Of Discount NotesPayableNetOfDiscount	1245853	usd
CY2023Q1	adtx	Financing Of Fixed Asset Long Term FinancingOfFixedAssetLongTerm	147823	usd
CY2022Q4	adtx	Financing Of Fixed Asset Long Term FinancingOfFixedAssetLongTerm	409983	usd
CY2023Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	185586	usd
CY2022Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	188581	usd
CY2023Q1	adtx	Operating Lease Liability Short Term Current OperatingLeaseLiabilityShortTermCurrent	1094677	usd
CY2022Q4	adtx	Operating Lease Liability Short Term Current OperatingLeaseLiabilityShortTermCurrent	1086658	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5910229	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3643724	usd
CY2023Q1	adtx	Operating Lease Liability Long Term Noncurrent OperatingLeaseLiabilityLongTermNoncurrent	1655336	usd
CY2022Q4	adtx	Operating Lease Liability Long Term Noncurrent OperatingLeaseLiabilityLongTermNoncurrent	1885218	usd
CY2023Q1	us-gaap	Liabilities Liabilities	7565565	usd
CY2022Q4	us-gaap	Liabilities Liabilities	5528942	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4834731	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4307487	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4832714	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4305470	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	4835	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4307	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2017	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2017	shares
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	201605	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	201605	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101289906	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	100443967	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101025068	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95040362	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	68068	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5206307	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7633633	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10735249	usd
CY2023Q1	us-gaap	Revenues Revenues	218415	usd
CY2022Q1	us-gaap	Revenues Revenues	210279	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	178309	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	188071	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	40106	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	22208	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4368843	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4624158	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1387541	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1428382	usd
CY2023Q1	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	65617	usd
CY2022Q1	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	86599	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	5822001	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	6139139	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5781895	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6116931	usd
CY2023Q1	us-gaap	Interest Expense Other InterestExpenseOther	198492	usd
CY2022Q1	us-gaap	Interest Expense Other InterestExpenseOther	15210	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	9074	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	14040	usd
CY2022Q1	us-gaap	Other Income OtherIncome	58960	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	13393	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-202811	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	57790	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5984706	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6059141	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5984706	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6059141	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.31
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.8
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4562873	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	891614	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5206307	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	59964	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	111187	usd
CY2023Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	507016	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	168300	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5984706	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	68068	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10180773	usd
CY2022Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	219885	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	377671	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3719	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-6059141	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	4722907	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-5984706	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-6059141	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	339451	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	601275	usd
CY2023Q1	us-gaap	Depreciation Depreciation	109896	usd
CY2022Q1	us-gaap	Depreciation Depreciation	96852	usd
CY2023Q1	adtx	Disposal Of Fixed Assets1 DisposalOfFixedAssets1	26750	usd
CY2022Q1	adtx	Disposal Of Fixed Assets1 DisposalOfFixedAssets1	26750	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-198940	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	158933	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	51533	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	74841	usd
CY2023Q1	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	54940	usd
CY2022Q1	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	67587	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-186563	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	547258	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1277788	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	983579	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3951791	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5199304	usd
CY2023Q1	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	5049	usd
CY2022Q1	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	147802	usd
CY2022Q1	adtx	Ti Allowance Receivable TIAllowanceReceivable	211661	usd
CY2022Q1	adtx	Note Receivables And Accrued Interest NoteReceivablesAndAccruedInterest	13904	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5049	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-373367	usd
CY2023Q1	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	1245853	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	507016	usd
CY2023Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	262160	usd
CY2022Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	184184	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1490709	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-184184	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2466131	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5756855	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2768640	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7872061	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	302509	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2115206	usd
CY2023Q1	us-gaap	Interest Expense Other Long Term Debt InterestExpenseOtherLongTermDebt	193175	usd
CY2022Q3	adtx	Reverse Split Description ReverseSplitDescription	On September 13, 2022, the Company effectuated a 1 for 50 reverse stock split (the “Reverse Split”).
CY2021Q3	us-gaap	Common Unit Issued CommonUnitIssued	91667	shares
CY2021Q3	us-gaap	Accelerated Share Repurchases Initial Price Paid Per Share AcceleratedShareRepurchasesInitialPricePaidPerShare	120
CY2021Q3	us-gaap	Demutualization By Insurance Entity Securities Issued Gross Cash Proceeds DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds	11000000	usd
CY2021Q3	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	91667	shares
CY2021Q3	adtx	Debt Instrument Term Description DebtInstrumentTermDescription	The warrants have an exercise price of $126.50 per share and are exercisable for a five-year period commencing six months from the date of issuance.
CY2021Q3	adtx	Warrants Exercise Price WarrantsExercisePrice	75
CY2021Q3	adtx	Purchase Of Common Stock PurchaseOfCommonStock	4584	shares
CY2021Q4	us-gaap	Common Unit Issued CommonUnitIssued	56667	shares
CY2021Q4	adtx	Exercise Price Per Shares ExercisePricePerShares	75
CY2021Q4	us-gaap	Demutualization By Insurance Entity Securities Issued Gross Cash Proceeds DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds	4250000	usd
CY2021Q4	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	3910000	usd
CY2021Q4	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	16000000	usd
CY2021Q4	us-gaap	Common Unit Issued CommonUnitIssued	164929	shares
CY2021Q4	adtx	Prefunded Warrants Shares PrefundedWarrantsShares	166572	shares
CY2021Q4	adtx	Exercise Price Per Shares ExercisePricePerShares	57.5
CY2022Q3	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	17200000	usd
CY2022Q3	adtx	Purchase Of Equity Shares PurchaseOfEquityShares	2109000	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	3333333	shares
CY2022Q3	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	6
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.001
CY2023Q1	us-gaap	Interest Paid InterestPaid	5984706	usd
CY2023Q1	adtx	Net Loss Cash Flow From Operating Activities NetLossCashFlowFromOperatingActivities	3951791	usd
CY2023Q1	us-gaap	Cash Cash	302509	usd
CY2022Q2	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	7900000	usd
CY2023Q1	us-gaap	Investment Company Registration Expense InvestmentCompanyRegistrationExpense	51000000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the financial statements include the collectability of notes receivable, collectability and reserve on accounts receivable, the reserve on insurance billing, and the fair value of stock options and warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Substantially all the Company’s accounts receivable are with companies in the healthcare industry, individuals, and the U.S. government. However, concentration of credit risk is mitigated due to the Company’s number of customers. In addition, for receivables due from U.S government agencies, the Company does not believe the receivables represent a credit risk as these are related to healthcare programs funded by the U.S. government and payment is primarily dependent upon submitting the appropriate documentation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	18634	usd
CY2023Q1	adtx	Licensing Fee For Patents LicensingFeeForPatents	60000	usd
CY2022Q1	adtx	Licensing Fee For Patents LicensingFeeForPatents	225013	usd
CY2023Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	1387541	usd
CY2022Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	1148382	usd
CY2023Q1	adtx	Warrants Of Stock Options WarrantsOfStockOptions	44710	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	4267	shares
CY2023Q1	adtx	Dilutive Earning Shares DilutiveEarningShares	5079348	shares
CY2022Q1	adtx	Warrants Of Stock Options WarrantsOfStockOptions	44710	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	20373	shares
CY2022Q1	adtx	Warrants Exercised Shares WarrantsExercisedShares	600252	shares
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3139901	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	925885	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2214016	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3134850	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	815987	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2318863	usd
CY2023Q1	us-gaap	Depreciation Depreciation	109896	usd
CY2022Q1	us-gaap	Depreciation Depreciation	96852	usd
CY2023Q1	us-gaap	Time Deposits At Carrying Value TimeDepositsAtCarryingValue	1316830	usd
CY2022Q4	us-gaap	Time Deposits At Carrying Value TimeDepositsAtCarryingValue	1359091	usd
CY2020Q4	us-gaap	Equipment Expense EquipmentExpense	19487	usd
CY2020Q4	us-gaap	Derivative Average Cap Interest Rate DerivativeAverageCapInterestRate	0.08	pure
CY2021Q1	us-gaap	Equipment Expense EquipmentExpense	9733	usd
CY2021Q1	us-gaap	Derivative Average Cap Interest Rate DerivativeAverageCapInterestRate	0.08	pure
CY2021Q1	us-gaap	Equipment Expense EquipmentExpense	37171	usd
CY2021Q1	us-gaap	Derivative Average Cap Interest Rate DerivativeAverageCapInterestRate	0.08	pure
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	321000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	240750	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	80250	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	321000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	214000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	107000	usd
CY2023Q1	adtx	Amortization Of Intangible Asset AmortizationOfIntangibleAsset	26750	usd
CY2022Q1	adtx	Amortization Of Intangible Asset AmortizationOfIntangibleAsset	26750	usd
CY2023Q1	us-gaap	Intermediate Life Plants Useful Life IntermediateLifePlantsUsefulLife	P3Y
CY2023Q1	adtx	Gross Proceeds GrossProceeds	1500000	usd
CY2023Q1	us-gaap	Legal Fees LegalFees	75000	usd
CY2023Q1	adtx	Warrant Exercise Price WarrantExercisePrice	1307460
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	61607	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	297091	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	322495	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	297091	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	322495	usd
CY2023Q1	adtx	Right Of Use Asset Short Term RightOfUseAssetShortTerm	2935599	usd
CY2022Q4	adtx	Right Of Use Asset Short Term RightOfUseAssetShortTerm	3160457	usd
CY2023Q1	adtx	Total Right Of Use Asset TotalRightOfUseAsset	2935599	usd
CY2022	adtx	Total Right Of Use Asset TotalRightOfUseAsset	3160457	usd
CY2023Q1	adtx	Operating Lease Liabilities Short Term OperatingLeaseLiabilitiesShortTerm	1094677	usd
CY2022Q4	adtx	Operating Lease Liabilities Short Term OperatingLeaseLiabilitiesShortTerm	1086658	usd
CY2023Q1	adtx	Operating Lease Liabilities Long Term OperatingLeaseLiabilitiesLongTerm	1655336	usd
CY2022Q4	adtx	Operating Lease Liabilities Long Term OperatingLeaseLiabilitiesLongTerm	1885218	usd
CY2023Q1	adtx	Total Lease Liability TotalLeaseLiability	2750013	usd
CY2022Q4	adtx	Total Lease Liability TotalLeaseLiability	2971876	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M26D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	851883	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1004982	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	710546	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	423930	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2991341	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	241328	usd
CY2023Q1	adtx	Operating Leases Liability Current OperatingLeasesLiabilityCurrent	1094677	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1655336	usd
CY2023Q1	us-gaap	Shares Issued SharesIssued	187000	shares
CY2023Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	500	shares
CY2020Q3	us-gaap	Taxes And Licenses TaxesAndLicenses	455000	usd
CY2022Q1	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	175000	usd
CY2022Q1	us-gaap	Other Payments To Acquire Businesses OtherPaymentsToAcquireBusinesses	175000	usd
CY2022Q1	srt	Extensions Discoveries Additions And Improved Recovery Less Related Costs ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts	100000	usd
CY2018	us-gaap	Information Technology And Data Processing InformationTechnologyAndDataProcessing	70000	usd
CY2019Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	60000	usd
CY2023Q1	us-gaap	Product Liability Contingency Third Party Recovery Percentage ProductLiabilityContingencyThirdPartyRecoveryPercentage	0.0075	pure
CY2023Q1	adtx	Expiration Period ExpirationPeriod	P3Y
CY2022Q1	us-gaap	Investment Company Fee Paid Indirectly InvestmentCompanyFeePaidIndirectly	100000	usd
CY2020Q1	us-gaap	Investment Company Fee Paid Indirectly InvestmentCompanyFeePaidIndirectly	25000	usd
CY2023Q1	us-gaap	Shares Issued SharesIssued	375	shares
CY2023Q1	us-gaap	Sale Leaseback Transaction Other Payments Required SaleLeasebackTransactionOtherPaymentsRequired	25000	usd
CY2023Q1	adtx	Payment Of Milestone Fees PaymentOfMilestoneFees	50000	usd
CY2023Q1	us-gaap	Clearance Fees ClearanceFees	25000	usd
CY2022Q1	us-gaap	Registration Payment Arrangement Maximum Potential Consideration RegistrationPaymentArrangementMaximumPotentialConsideration	25000	usd
CY2020Q2	us-gaap	Financial Guarantee Insurance Contracts Accelerated Premium Revenue Amount FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount	10000000	usd
CY2023Q1	us-gaap	Broadcasters License Agreement Commitments Description BroadcastersLicenseAgreementCommitmentsDescription	In addition to the annual license maintenance fees outlined above, we will pay Stanford royalties on Net Sales (as such term is defined in the February 2020 License Agreement) during the of the term of the agreement as follows: 4% when Net Sales are below or equal to $5 million annually or 6% when Net Sales are above $5 million annually.
CY2023Q1	us-gaap	Liabilities Average Amount Outstanding LiabilitiesAverageAmountOutstanding	1800000	usd
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On September 13, 2022, the Company effectuated a 1 for 50 reverse stock split (the “Reverse Split”).
CY2023Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation Gross StockIssuedDuringPeriodSharesShareBasedCompensationGross	187000	shares
CY2023Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	168300	usd
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	50000000	shares
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	338513	shares
CY2023Q1	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	1.55
CY2023Q1	us-gaap	Insurance Commissions And Fees InsuranceCommissionsAndFees	507016	usd
CY2022Q1	adtx	Preferred Stock Par Value PreferredStockParValue	0.001
CY2022Q3	adtx	Shares Of Common Stock SharesOfCommonStock	1	shares
CY2022Q3	us-gaap	Assets Sold Under Agreements To Repurchase Repurchase Liability AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability	20000	usd
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	250000000	shares
CY2023Q1	us-gaap	Redemption Premium RedemptionPremium	20000	usd
CY2022Q4	adtx	Company Paid CompanyPaid	20000	usd
CY2022Q4	us-gaap	Preferred Stock Dividends Shares PreferredStockDividendsShares	1	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	60000	shares
CY2021Q1	adtx	Fair Market Value FairMarketValue	1	pure
CY2023Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	43360	shares
CY2023Q1	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	172.3
CY2023Q1	adtx	Share Based Payment Remnaining Expenses ShareBasedPaymentRemnainingExpenses	119928	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1	P0Y6M
CY2022Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	133660	usd
CY2023Q1	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	0	usd
CY2022Q1	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	26262	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
CY2023Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	111187	usd
CY2022Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	377671	usd
CY2023Q1	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	2503	usd
CY2023Q1	adtx	Rs Us Vested RSUsVested	1731	shares
CY2023Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	1731	shares
CY2023Q1	adtx	Shares Of Common Stockvested Rs Us SharesOfCommonStockvestedRSUs	1731
CY2022Q4	adtx	Notes Payable Net Of Discount NotesPayableNetOfDiscount		usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Other Income OtherIncome		usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.80
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4562873	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	891614	shares
CY2023Q1	adtx	Ti Allowance Receivable TIAllowanceReceivable		usd
CY2023Q1	adtx	Note Receivables And Accrued Interest NoteReceivablesAndAccruedInterest		usd
CY2022Q1	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable		usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022Q1	us-gaap	Interest Expense Other Long Term Debt InterestExpenseOtherLongTermDebt		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P0Y
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001726711

Files In Submission

Name	View Source	Status
adtx-20230331_def.xml	Edgar Link	unprocessable
0001213900-23-039839-index-headers.html	Edgar Link	pending
0001213900-23-039839-index.html	Edgar Link	pending
0001213900-23-039839.txt	Edgar Link	pending
0001213900-23-039839-xbrl.zip	Edgar Link	pending
adtx-20230331.xsd	Edgar Link	pending
f10q0323ex31-1_aditxt.htm	Edgar Link	pending
f10q0323ex31-2_aditxt.htm	Edgar Link	pending
f10q0323ex32-1_aditxt.htm	Edgar Link	pending
f10q0323_aditxt.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
adtx-20230331_cal.xml	Edgar Link	unprocessable
adtx-20230331_lab.xml	Edgar Link	unprocessable
adtx-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0323_aditxt_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADTX
Aditxt, Inc. Stock $adtx

2023 Q1 Form 10-Q Financial Statement

#000121390023039839 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADTX Aditxt, Inc. Stock $adtx

2023 Q1 Form 10-Q Financial Statement

#000121390023039839 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADTX
Aditxt, Inc. Stock $adtx